TRODELVY (sacituzumab govitecan-hziy) for injection

TRODELVY is a prescription medicine used to treat adults with: • a type of breast cancer that is estrogen and progesterone hormone receptor (HR) negative, and human epidermal growth factor receptor 2 (HER2)-negative (also called triple-negative breast cancer). • bladder cancer and cancers of the urinary tract that have spread or cannot be removed by surgery.

Home | (sacituzumab govitecan-hziy) for injection

TRODELVY (sacituzumab govitecan-hziy) for injection Price In India and Overseas
TRODELVY (sacituzumab govitecan-hziy) for injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

TRODELVY (sacituzumab govitecan-hziy) for injection

Sacituzumab govitecan-hziy is approved to treat adults with: Breast cancer, Urothelial cancer (a type of cancer in the bladder or urinary tract). Sacituzumab govitecan-hziy is also being studied in the treatment of other types of cancer.

Trodelvy, A drug used to treat adults with certain types of breast cancer or urothelial cancer (a type of cancer in the bladder or urinary tract) that have already been treated with other therapy. It is also being studied in the treatment of other types of cancer. Trodelvy contains a monoclonal antibody called sacituzumab that binds to a protein called TROP2, which is found on some cancer cells. It also contains an anticancer drug called SN-38, which may help kill cancer cells. Trodelvy is a type of antibody-drug conjugate. Also called sacituzumab govitecan.

Sacituzumab Govitecan-hziy, Sacituzumab govitecan-hziy is a type of targeted therapy called an antibody-drug conjugate. It is made of a monoclonal antibody chemically linked to a cancer-killing drug. The monoclonal antibody binds to a protein on the surface of some cancer cells. The linked drug enters these cancer cells and kills them. Sacituzumab govitecan-hziy may also stimulate the immune system to kill cancer cells.

Drug (Brand / Generic): TRODELVY / sacituzumab govitecan-hziy
Current Indications: chronic breast cancer or urothelial cancer
Marketed by:: Gilead Sciences, Inc
Approval Date: 2020

Available as (Form & Strength): For injection: 180 mg lyophilized powder in single-dose vials for reconstitution.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.